Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
Kimio Yonesaka, Kreshnik Zejnullahu, Isamu Okamoto et al. · Science Translational Medicine · 2011
Cetuximab, an antibody directed against the epidermal growth factor receptor, is an effective clinical therapy for patients with colorectal, head and neck, and non-small cell lung cancer, particularly for those with KRAS and BRAF wild-type cancers. Treatment in all patients is limited eventually by the development of acquired resistance, but little is known about the underlying mechanism. Here, we show that activation of ERBB2 signaling in cell lines, either through ERBB2 amplification or through heregulin up-regulation, leads to persistent extracellular signal-regulated kinase 1/2 signaling and consequently to cetuximab resistance. Inhibition of ERBB2 or disruption of ERBB2/ERBB3 heterodimerization restores cetuximab sensitivity in vitro and in vivo. A subset of colorectal cancer patients who exhibit either de novo or acquired resistance to cetuximab-based therapy has ERBB2 amplification or high levels of circulating heregulin. Collectively, these findings identify two distinct resistance mechanisms, both of which promote aberrant ERBB2 signaling, that mediate cetuximab resistance. Moreover, these results suggest that ERBB2 inhibitors, in combination with cetuximab, represent a rational therapeutic strategy that should be assessed in patients with cetuximab-resistant cancers.
Cited by 663 works. doi:10.1126/scitranslmed.3002442
Authors
- Kimio Yonesaka
- Kreshnik Zejnullahu
- Isamu Okamoto
- Taroh Satoh
- Federico Cappuzzo
- John Souglakos
- Dalia Ercan
- Andrew M. Rogers
- Massimo G. Roncalli
- Masayuki Takeda
- Yasuhito Fujisaka
- Juliet Philips
- Toshio Shimizu
- Osamu Maenishi
- Yong Gon Cho
- Jason Sun
- Annarita Destro
- Koichi Taira
- Takafumi Okabe
References
- EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
- Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
- K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
- First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations
- Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
- Phase I Studies of Anti–Epidermal Growth Factor Receptor Chimeric Antibody C225 Alone and in Combination With Cisplatin